Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.

Cancer research - 15 Nov 2017

Brady Donita C, Crowe Matthew S, Greenberg Danielle N, Counter Christopher M

Abstract excerpt

MEK1/2 and BRAFV600E inhibitors are used to treat BRAFV600E-positive melanoma, with other cancers under evaluation. Genetic perturbation of copper import or pharmacologic reduction of copper with the clinical copper chelator TTM inhibits MEK1/2 kinase activity and reduces BRAFV600E-driven tumorigenesis. In this study, we report that TTM inhibited transformed growth of melanoma cell lines resistant to BRAF or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Chelating Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Copper

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Melanoma, Experimental

Share to Molybdenum

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 28986383
DOI: 10.1158/0008-5472.CAN-16-1190
PMCID: PMC5690876

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.PMID 28986383Read ↗

Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.Semantic proximity Read ↗

BRAFV600E-Driven Lung Adenocarcinoma Requires Copper to Sustain Autophagic Signaling and ProcessingSemantic proximity Read ↗

Augmenting MEK inhibitor Efficacy in BRAF Wild-Type Melanoma: Synergistic Effects of Disulfiram Combination TherapySemantic proximity Read ↗

Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.Semantic proximity Read ↗

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanomaSemantic proximity Read ↗

MCU controls melanoma progression through a redox-controlled phenotype switch.Semantic proximity Read ↗

Copper: An Intracellular Achilles’ Heel Allowing the Targeting of Epigenetics, Kinase Pathways, and Cell Metabolism in Cancer TherapeuticsSemantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Toxicogenomic and bioinformatics platforms to identify key molecular mechanisms of a curcumin-analogue DM-1 toxicity in melanoma cells.Semantic proximity Read ↗

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.Semantic proximity Read ↗

Targeted therapy for melanoma: rational combinatorial approaches.Semantic proximity Read ↗

Molecular approaches to tumor inhibition in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.